New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC working group on thrombosis - Task force on anticoagulants in heart disease position paper

Journal of the American College of Cardiology

Volumn 59, Issue 16, 2012, Pages 1413-1425

  De Caterina, Raffaele ^a,b   Husted, Steen ^c   Wallentin, Lars ^d   Andreotti, Felicita ^e   Arnesen, Harald ^f   Bachmann, Fedor ^g   Baigent, Colin ^h   Huber, Kurt ⁱ   Jespersen, Jørgen ^j   Kristensen, Steen Dalby ^c   Lip, Gregory Y H ^k   Morais, Joo ^l   Rasmussen, Lars Hvilsted ^m   Siegbahn, Agneta ^d   Verheugt, Freek W A ⁿ   Weitz, Jeffrey I ^o  

^a UNIVERSITY OF CHIETI   (Italy)

^b Fondazione Toscana G Monasterio   (Italy)

^c AARHUS UNIVERSITY   (Denmark)

^d UPPSALA UNIVERSITY   (Sweden)

^e CATHOLIC UNIVERSITY   (Italy)

^f ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^g UNIVERSITY OF LAUSANNE   (Switzerland)

^h UNIVERSITY OF OXFORD   (United Kingdom)

ⁱ WILHELMINEN HOSPITAL   (Austria)

^j UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^k UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^l Cardiology Division Santo Andrés Hospital   (Portugal)

^m AALBORG UNIVERSITY   (Denmark)

ⁿ ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

^o MCMASTER UNIVERSITY   (Canada)

more..

Author keywords

acute coronary syndromes; anticoagulants; apixaban; atrial fibrillation; dabigatran etexilate; edoxaban; rivaroxaban; vitamin K antagonists

Indexed keywords

ACETYLSALICYLIC ACID; ACTIVATED CARBON; ANTIVITAMIN K; APIXABAN; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 7; CARBAMAZEPINE; CLOPIDOGREL; CYTOCHROME P450 2J2; CYTOCHROME P450 3A4; DABIGATRAN ETEXILATE; DAREXABAN; DRONEDARONE; EDOXABAN; FIBRIN; FIBRINOGEN; FRESH FROZEN PLASMA; HYPERICUM PERFORATUM EXTRACT; PHENYTOIN; PLACEBO; PRASUGREL; PROTHROMBIN COMPLEX; QUINIDINE; RIFAMPICIN; RIVAROXABAN; THROMBIN; TICAGRELOR; UNINDEXED DRUG; VERAPAMIL; WARFARIN;

ACUTE CORONARY SYNDROME; ANTICOAGULATION; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CLINICAL PRACTICE; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG OVERDOSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG TRANSFORMATION; DRUG WITHDRAWAL; EMBOLISM; EPISTAXIS; GASTROINTESTINAL HEMORRHAGE; GINGIVA BLEEDING; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEMATOMA; HEMATURIA; HUMAN; INTERNATIONAL NORMALIZED RATIO; LIVER TOXICITY; MORTALITY; MULTICENTER STUDY (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; SKIN BRUISING; STROKE; TREATMENT DURATION; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 84859603846     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2012.02.008     Document Type: Review

References (34)

1. R. De Caterina, S. Husted, L. Wallentin Anticoagulants in heart disease: current status and perspectives Eur Heart J 28 2007 880 913 (Pubitemid 47343588)
2. C. Patrono, F. Andreotti, H. Arnesen Antiplatelet agents for the treatment and prevention of atherothrombosis Eur Heart J 32 2011 2922 2932
3. W.G. Eisert, N. Hauel, J. Stangier, W. Wienen, A. Clemens, J. van Ryn Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin Arterioscler Thromb Vasc Biol 30 2010 1885 1889
4. J.I. Weitz Factor Xa and thrombin as targets for new oral anticoagulants Thromb Res 127 Suppl 2 2011 S5 S12
5. L.A. Sorbera, J. Bozzo, J. Castaner Dabigatran/dabigatran etexilate Drugs Fut 30 2005 877 885
6. J. Stangier, B.I. Eriksson, O.E. Dahl Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement J Clin Pharmacol 45 2005 555 563 (Pubitemid 40562946)
7. B.I. Eriksson, O.E. Dahl, L. Ahnfelt Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I J Thromb Haemost 2 2004 1573 1580 (Pubitemid 40186173)
8. E.S. Eerenberg, P.W. Kamphuisen, M.K. Sijpkens, J.C. Meijers, H.R. Buller, M. Levi Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects Circulation 124 2011 1573 1579
9. J. Jiang, Y. Hu, J. Zhang Safety, pharmacokinetics and pharmacodynamics of single doses of rivaroxaban - an oral, direct factor Xa inhibitor - in elderly Chinese subjects Thromb Haemost 103 2010 234 241
10. C.T. Ruff, R.P. Giugliano, E.M. Antman Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48) Am Heart J 160 2010 635 641
11. J.I. Weitz, S.J. Connolly, I. Patel Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation Thromb Haemost 104 2010 633 641
12. M.D. Ezekowitz, P.A. Reilly, G. Nehmiz Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study) Am J Cardiol 100 2007 1419 1426 (Pubitemid 47576022)
13. R. Nagarakanti, M.D. Ezekowitz, K. Parcham-Azad Long-term open label extension of the prevention of embolic and thrombotic events on dabigatran in atrial fibrillation (PETRO-Ex study) Circulation 118 2008 18
14. S.J. Connolly, M.D. Ezekowitz, S. Yusuf Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 2009 1139 1151
15. S.J. Connolly, M.D. Ezekowitz, S. Yusuf, P.A. Reilly, L. Wallentin Newly identified events in the RE-LY trial N Engl J Med 363 2010 1875 1876
16. S.H. Hohnloser, J. Oldgren, S. Yang Myocardial Ischemic Events in Patients with Atrial Fibrillation Treated with Dabigatran or Warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulatoin Therapy) Trial Circulation 125 2012 669 676
17. L. Wallentin, S. Yusuf, M.D. Ezekowitz Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial Lancet 376 2010 975 983
18. M.R. Patel, K.W. Mahaffey, J. Garg Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N Engl J Med 365 2011 883 889
19. S.J. Connolly, J. Eikelboom, C. Joyner Apixaban in patients with atrial fibrillation N Engl J Med 364 2011 806 817
20. C.B. Granger, J.H. Alexander, J.J.V. McMurray ARISTOTLE Committees and Investigators Apixaban versus warfarin in patients with atrial fibrillation N Engl J Med 365 2011 981 992
21. K.A.A. Fox, P.G. Steg, K.A. Eagle GRACE Investigators Decline in rates of death and heart failure in acute coronary syndromes, 1999-2006 JAMA 297 2007 1892 1900 (Pubitemid 46707843)
22. K.A.A. Fox, O.H. Dabbous, R.J. Goldberg Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE) BMJ 333 2006 1091 1094 (Pubitemid 44863647)
23. M. Hurlen, M. Abdelnoor, P. Smith, J. Erikssen, H. Arnesen Warfarin, aspirin, or both after myocardial infarction N Engl J Med 347 2002 969 974
24. R. Sørensen, M.L. Hansen, S.Z. Abildstrom Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data Lancet 374 2009 1967 1974
25. J. Oldgren, A. Budaj, C.B. Granger Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial Eur Heart J 32 2011 2781 2789
26. J.L. Mega, E. Braunwald, S. Mohanavelu Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial Lancet 374 2009 29 38
27. J.H. Alexander, R.C. Becker, D.L. Bhatt Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial Circulation 119 2009 2877 2885
28. P.G. Steg, S.R. Mehta, J.W. Jukema RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome Eur Heart J 32 2011 2541 2554
29. J.H. Alexander, R.D. Lopes, S. James APPRAISE 2 Investigators Apixaban with antiplatelet therapy after acute coronary syndrome N Engl J Med 365 2011 699 708
30. C.M. Gibson, J.L. Mega, P. Burton Rationale and design of the Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome Am Heart J 161 2011 815 821.e6
31. J.L. Mega, E. Braunwald, S.D. Wiviott Rivaroxaban in patients with a recent acute coronary syndrome N Engl J Med 366 2012 9 19
32. M.L. Simoons, I.W. Bobbink, J. Boland A dose-finding study of fondaparinux in patients with non-ST-segment elevation acute coronary syndromes: the Pentasaccharide in Unstable Angina (PENTUA) Study J Am Coll Cardiol 43 2004 2183 2190 (Pubitemid 38757583)
33. C.W. Hamm, J.P. Bassand, S. Agewall ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC) Eur Heart J 32 2011 2999 3054
34. G.N. Levine, E.R. Bates, J.C. Blankenship 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions J Am Coll Cardiol 58 2011 e44 e122